



## Beverley Moore

Partner

T 613.369.4784  
F 613.230.8842  
Ottawa  
[BMoore@blg.com](mailto:BMoore@blg.com)  
[LinkedIn](#)

[Intellectual Property Litigation](#)  
[Life Sciences](#)  
[Intellectual Property](#)  
[Patents](#)  
[Trademarks](#)  
[Trade Policy & Negotiations](#)  
[Appellate Advocacy](#)  
[MedTech](#)  
[IP Strategy](#)

Beverley is national leader of BLG's Intellectual Property Litigation Group. She is an experienced trial lawyer and conducts trials and hearings in the Federal Court and Federal Court of Appeal. Beverley practises in all areas of intellectual property litigation, with a focus on complex patent and trademark disputes. Beverley also has significant experience with actions brought under the Patented Medicines (Notice of Compliance) Regulations.

Beverley represents clients in a multitude of sectors including life sciences, technology, gaming and mining for patent litigation. She is also interested in the intersection of IP and artificial intelligence as well as other emerging technologies.

Beverley regularly provides strategic advice to clients in all sectors on patent portfolio management and trade secrets. In addition, Beverley advises on patentability, validity and freedom-to-operate issues and has assisted in the IP components of transactions.

Having worked with life sciences and biotechnology companies throughout her career, Beverley uses that experience to provide strategic advice on navigating Canada's IP regulatory issues including listing patents on the Patent Register, reporting patents to the Patented Medicines Prices Review Board, Certificates of Supplementary Protection and the Register of Innovative Drugs as it relates to data protection. In addition,

Beverley advises on Access to Information requests, in particular those made to Health Canada by pharmaceutical clients.

Beverley consulted on the implementation and application of the intellectual property provisions of the Comprehensive Economic and Trade Agreement (CETA) between Canada and the European Union and has advised on the United States-Mexico-Canada Agreement (USMCA).

Beverley has advocated before the Federal Court and Federal Court of Appeal, the Patent Appeal Board and the Patented Medicine Prices Review Board.

Throughout her career, Beverley has been very active in the legal profession. She is one of the founding Co-chairs of the Eastern Canada Chapter of ChIPs. Beverley is the current chair of the CBA IP Section's Court Practice Committee, and is a member at large on the CBA IP Section executive. She sits on the Steering Committee for DRI's IP Litigation Committee. Beverley is one of the co-vice chairs of the IPOwners Association's newly formed Wellness committee, and is a past co-vice chair of IPO's Pharmaceutical and Biotechnology Issues Committee and its Canadian Practice Committee. In addition, Beverley is a regular speaker and writer on IP issues, and serves on the BLG's Thought Leadership Committee. Beverley is also both a formal and informal mentor to students and associates at BLG.

## Experience

- **Counsel for innovative companies asserting validity and infringement of patents during proceedings brought pursuant to the *NOC Regulations*.**
- **Counsel for innovative companies challenging and judicially reviewing the Minister of Health's refusal to list patents on the Patent Register.**
- **Counsel for innovative companies defending generic companies' claims for damages pursuant to s. 8 of the *NOC Regulations*.**
- Counsel for innovative companies in patent infringement and validity proceedings involving claims to **compounds, formulations and uses of drugs and the processes to make them**.
- Advising clients on **patent portfolio issues relating to data protection**, listing patents on the Patent Register and reporting to the Patented Medicines Prices Review Board.
- Preparing **freedom-to-operate, infringement and validity opinions** with respect to intellectual property matters.
- **Counsel for clients seeking leave to intervene and intervening in proceedings before the Supreme Court of Canada.**
- Counsel for clients seeking leave to intervene and intervening in proceedings before the Patented Medicines Prices Review Board.

## Insights & Events

- Author, "Infringement by common design found in Canadian case", BLG Article, December 2025
- Author, "Narrow issues of claim construction, double patenting, and costs determined on appeal", BLG Article, October 2025
- Author, "Patented Medicine Prices Review Board publishes new guidelines for PMPRB staff: Finally, some guidance for patentees", BLG Article, July 2025
- Author, "Can one infringe an apparatus patent with mere plans or drawings? The SCC's denial of leave confirms that the answer is no", BLG Article, July 2025

- Author, "Patent is NOT listed on Patent Register when Form IV is filed; only when Minister determines it is eligible", BLG Article, January 2025
- Author, "Patent term adjustment in Canada: More of a unicorn than a safety net", BLG Article, December 2024
- Author, "The FCA concludes PMPRB decision re Differin® exceeded the Board's jurisdiction", BLG Article, December 2024
- Author, "First court decision judicially reviewing decision of investigations committee of CPATA", BLG Article, September 2024
- Author, "Federal Court of Appeal in summary trial on ownership upholds finding that neither party owns the patent", BLG Article, August 2024
- Author, "Full particulars are required when pleading misrepresentation under s. 53 of the Patent Act", BLG Article, August 2024
- Author, "Excess claims fees vs. double patenting in Canadian prosecution", BLG Article, June 2024
- Author, "Legislative provisions delineating double patenting would be beneficial for all", BLG Article, June 2024
- Author, "PMPRB's decision that patent pertains to drug held to be reasonable by Federal Court", BLG Article, January 2024
- Author, "Court of Appeal finds abuse of process for second notice of allegation", BLG Article, January 2024
- Author, "The Patented Medicines Prices Review Board is consulting on new guidelines", BLG Article, November 2023
- Author, "Active consultation: Amendments to the Copyright Act relating to generative artificial intelligence", BLG Article, October 2023
- Author, "To intervene or not to intervene before the Federal Courts", BLG Article, October 2023
- Author, "Much anticipated FCA decision in Benjamin Moore removes prescriptive test ordered by FC", BLG Article, August 2023
- Author, "Patent term restoration in Canada", BLG Article, August 2023
- Author, "Accounting of profits remedy for patent infringement in Canada", BLG Article, June 2023
- Author, "Canada's new excess claims fees vs double patenting", BLG Article, June 2023
- Author, "Patent term adjustment is coming to Canada", BLG Article, April 2023
- Medical device litigation trends in Canada and the U.S., BLG Video, April 2023
- Author, "SCC provides clarity on accounting of profits remedy in patent infringement", BLG Article, November 2022
- Author, "Navigating new excess claims fees and double patenting risk in Canadian patent prosecution: The devil and the deep blue sea", BLG Article, September 2022

## Beyond Our Walls

### Professional Involvement

- Vice Co-Chair, Intellectual Property Owners Association (IPO), Pharmaceutical & Biotechnology Issues Committee
- Member, Intellectual Property Institute of Canada (IPIC), IPIC Editorial Board for the Canadian Intellectual Property Review, IPIC Competition Law
- Director, "Understanding Patents" course as part of the IPIC/McGill Summer Courses in Intellectual Property, 2020-2021
- Assistant Director, "Understanding Patents" course as part of the IPIC/McGill Summer Courses in Intellectual Property, 2018-2020
- Member, Canadian Bar Association (CBA), Court Practice Committee

- Member, Advocate's Society
- Member, County of Carleton Law Association
- Member, BIOTECanada's Health Advisory Board and Subsequent Entry Biologics Task Force
- Member, Chiefs in Intellectual Property (ChIPs)

## Awards & Recognition

- Recognized as Patent Prosecution Practitioner of the Year in the *Managing IP* 2025 Americas Awards. Beverley is also named one of the Top 250 Women in IP 2025 by *Managing IP*.
- Recognized in the 2026 edition (and since 2019) of *The Best Lawyers in Canada®* (Intellectual Property Law) and in the 2020 edition (Biotechnology).
- Selected by peers for inclusion in the 2025 edition (and since 2023) of *Canadian Legal Lexpert Directory®* (Intellectual Property; Life Sciences & Health) and in the 2023-2024 editions (Litigation – Intellectual Property).
- Recognized in the 2024 and previous editions of *IAM Patent 1000* (Bronze - Litigation)
- Recognized in the 2025 edition (and since 2022) of *Lexpert Special Edition: Technology*.
- Recognized in the 2025 edition (and since 2022) of *Lexpert Special Edition: Health Sciences*.
- Recognized in the 2023 edition of *Lexpert Special Edition Litigation*
- Recognized in the 2024 edition (and since 2021) of *Who's Who Legal Canada - Life Sciences - Patent Litigation*
- Recognized in the 2021 edition of *Lexpert Special Edition: Health Sciences*.
- Recognized in the 2021 edition of *Lexpert Special Edition: Technology*.
- Recognized in the 2020 - 2022 editions of *Managing Intellectual Property's IP Stars* (Patent).

## Bar Admission & Education

- Ontario, 2003
- LLB, Queen's University, 2002
- MSc, Biochemistry, Queen's University, 2000
- BSc (Hons.), Biochemistry, Queen's University, 1997

---

## BLG | Canada's Law Firm

As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 800 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.

[blg.com](http://blg.com)

© 2026 Borden Ladner Gervais LLP. Borden Ladner Gervais LLP is an Ontario Limited Liability Partnership.